Akiko Kimura
Osaka University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Akiko Kimura.
Journal of Biological Chemistry | 2002
Seiji Mabuchi; Masahide Ohmichi; Akiko Kimura; Koji Hisamoto; Jun Hayakawa; Yukihiro Nishio; Kazushige Adachi; Kazuhiro Takahashi; Emi Arimoto-Ishida; Yuki Nakatsuji; Keiichi Tasaka; Yuji Murata
We studied the roles of the phosphatidylinositol 3-kinase (PI-3K)-Akt-BAD cascade, ERK-BAD cascade, and Akt-Raf-1 cascade in the paclitaxel-resistant SW626 human ovarian cancer cell line, which lacks functional p53. Treatment of SW626 cells with paclitaxel activates Akt and ERK with different time frames. Interference with the Akt cascade either by treatment with PI-3K inhibitor (wortmannin or LY294002) or by exogenous expression of a dominant negative Akt in SW626 cells caused decreased cell viability following treatment with paclitaxel. Interference with the ERK cascade by treatment with an MEK inhibitor, PD98059, in SW626 cells also caused decreased cell viability following treatment with paclitaxel. Treatment of cells with paclitaxel also stimulated the phosphorylation of BAD at both the Ser-112 and Ser-136 sites. The phosphorylation of BAD at Ser-136 was blocked by treatment with wortmannin or cotransfection with the dominant negative Akt. On the other hand, the phosphorylation of BAD at Ser-112 was blocked by PD98059. We further examined the role of BAD in the viability following paclitaxel treatment using BAD mutants. Exogenous expression of doubly substituted BAD2SA in SW626 cells caused decreased viability following treatment with paclitaxel. Moreover, because paclitaxel-induced apoptosis is mediated by activated Raf-1 and the region surrounding Ser-259 in Raf-1 conforms to a consensus sequence for phosphorylation by Akt, the regulation of Raf-1 by Akt was examined. We demonstrated an association between Akt and Raf-1 and showed that the phosphorylation of Raf-1 on Ser-259 induced by paclitaxel was blocked by treatment with wortmannin or LY294002. Furthermore, interference with the Akt cascade induced by paclitaxel up-regulated Raf-1 activity, and expression of constitutively active Akt inhibited Raf-1 activity, suggesting that Akt negatively regulates Raf-1. Our findings suggest that paclitaxel induces the phosphorylation of BAD Ser-112 via the ERK cascade, and the phosphorylation of both BAD Ser-136 and Raf-1 Ser-259 via the PI-3K-Akt cascade, and that inhibition of either of these cascades sensitizes ovarian cancer cells to paclitaxel.
Endocrinology | 1997
Masahide Ohmichi; Koji Koike; Akiko Kimura; Kanji Masuhara; Hiromasa Ikegami; Yoshihide Ikebuchi; Tohru Kanzaki; Kazushige Touhara; Motoyoshi Sakaue; Yuzuru Kobayashi; Masuo Akabane; Akira Miyake; Yuji Murata
In this study, prostaglandin (PG) F2α was found to activate mitogen-activated protein (MAP) kinase and MAP kinase kinase (MEK) in cultured rat puerperal uterine myometrial cells. PGF2α stimulation also led to an increase in phosphorylation of raf-1, son of sevenless (SOS), and Shc. Furthermore, we examined the mechanism by which PGF2α induced MAP kinase phosphorylation. Both pertussis toxin (10 ng/ml), which inactivates Gi/Go proteins, and expression of a peptide derived from the carboxyl terminus of the β-adrenergic receptor kinase 1 (βARK1), which specifically blocks signaling mediated by the βγ subunits of G proteins, blocked the PGF2α-induced activation of MAP kinase. Ritodrine (1 μm), which is known to relax uterine muscle contraction, attenuated PGF2α-induced tyrosine phosphorylation of MAP kinase. Moreover, to examine the role of MAP kinase pathway in uterine contraction, an inhibitor of MEK activity, PD098059, was used. Although MEK inhibitor had no effect on PGF2α-induced calcium mobilization, th...
Journal of Biological Chemistry | 2000
Takeshi Yokoi; Masahide Ohmichi; Keiichi Tasaka; Akiko Kimura; Yuki Kanda; Jun Hayakawa; Masahiro Tahara; Koji Hisamoto; Hirohisa Kurachi; Yuji Murata
Endocrinology | 2004
Seiji Mabuchi; Masahide Ohmichi; Akiko Kimura; Yoshihide Ikebuchi; Koji Hisamoto; Emi Arimoto-Ishida; Yukihiro Nishio; Kazuhiro Takahashi; Keiichi Tasaka; Yuji Murata
Endocrinology | 2004
Emi Arimoto-Ishida; Masahide Ohmichi; Seiji Mabuchi; Toshifumi Takahashi; Chika Ohshima; Jun Hayakawa; Akiko Kimura; Kazuhiro Takahashi; Yukihiro Nishio; Masahiro Sakata; Hirohisa Kurachi; Keiichi Tasaka; Yuji Murata
Journal of Biological Chemistry | 2000
Akiko Kimura; Masahide Ohmichi; Keiichi Tasaka; Yuki Kanda; Hiromasa Ikegami; Jun Hayakawa; Koji Hisamoto; Ken-ichirou Morishige; Shuji Hinuma; Hirohisa Kurachi; Yuji Murata
Endocrinology | 2004
Seiji Mabuchi; Masahide Ohmichi; Akiko Kimura; Yukihiro Nishio; Emi Arimoto-Ishida; Namiko Yada-Hashimoto; Keiichi Tasaka; Yuji Murata
Endocrinology | 1999
Akiko Kimura; Masahide Ohmichi; Takashi Takeda; Hirohisa Kurachi; Hiromasa Ikegami; Koji Koike; Kanji Masuhara; Jun Hayakawa; Tohru Kanzaki; Mamoru Kobayashi; Masuo Akabane; Masaki Inoue; Akira Miyake; Yuji Murata
Biochemical and Biophysical Research Communications | 1997
A. Nohara; Masahide Ohmichi; Koji Koike; Hiroaki Jikihara; Akiko Kimura; Kanji Masuhara; Hiromasa Ikegami; Masaki Inoue; Akira Miyake; Yuji Murata
Endocrinology | 1997
Takeshi Sawada; Masahide Ohmichi; Koji Koike; Yuuki Kanda; Akiko Kimura; Kanji Masuhara; Hiromasa Ikegami; Masaki Inoue; Akira Miyake; Yuji Murata